• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Chem . Identification of Potent, Broad-Spectrum Coronavirus Main Protease Inhibitors for Pandemic Preparedness

tetano

Editor, Senior Moderator
J Med Chem


. 2024 Sep 27.
doi: 10.1021/acs.jmedchem.4c01404. Online ahead of print. Identification of Potent, Broad-Spectrum Coronavirus Main Protease Inhibitors for Pandemic Preparedness

David T Barkan[SUP] 1 [/SUP], Keira Garland[SUP] 2 [/SUP], Lei Zhang[SUP] 2 [/SUP], Richard T Eastman[SUP] 3 [/SUP], Matthew Hesse[SUP] 2 [/SUP], Mark Knapp[SUP] 4 [/SUP], Elizabeth Ornelas[SUP] 4 [/SUP], Jenny Tang[SUP] 4 [/SUP], Wilian Augusto Cortopassi[SUP] 2 [/SUP], Yu Wang[SUP] 5 [/SUP], Frederick King[SUP] 5 [/SUP], Weiping Jia[SUP] 2 [/SUP], Zachary Nguyen[SUP] 1 [/SUP], Andreas O Frank[SUP] 2 [/SUP], Ryan Chan[SUP] 3 [/SUP], Eric Fang[SUP] 4 [/SUP], Daniel Fuller[SUP] 1 [/SUP], Scott Busby[SUP] 1 [/SUP], Heidi Carias[SUP] 4 [/SUP], Kristine Donahue[SUP] 4 [/SUP], Laura Tandeske[SUP] 4 [/SUP], Thierry T Diagana[SUP] 3 [/SUP], Nadine Jarrousse[SUP] 3 [/SUP], Heinz Moser[SUP] 2 [/SUP], Christopher Sarko[SUP] 2 [/SUP], Dustin Dovala[SUP] 4 [/SUP], Stephanie Moquin[SUP] 3 [/SUP], Vanessa M Marx[SUP] 2 [/SUP]



Affiliations
Abstract

The COVID-19 pandemic highlights the ongoing risk of zoonotic transmission of coronaviruses to global health. To prepare for future pandemics, it is essential to develop effective antivirals targeting a broad range of coronaviruses. Targeting the essential and clinically validated coronavirus main protease (M[SUP]pro[/SUP]), we constructed a structurally diverse M[SUP]pro[/SUP] panel by clustering all known coronavirus sequences by M[SUP]pro[/SUP] active site sequence similarity. Through screening, we identified a potent covalent inhibitor that engaged the catalytic cysteine of SARS-CoV-2 Mpro and used structure-based medicinal chemistry to develop compounds in the pyrazolopyrimidine sulfone series that exhibit submicromolar activity against multiple M[SUP]pro[/SUP] homologues. Additionally, we solved the first X-ray cocrystal structure of M[SUP]pro[/SUP] from the human-infecting OC43 coronavirus, providing insights into potency differences among compound-target pairs. Overall, the chemical compounds described in this study serve as starting points for the development of antivirals with broad-spectrum activity, enhancing our preparedness for emerging human-infecting coronaviruses.


 
Back
Top